|
Atlantic Coastal Acquisition Corp Ii (ACAB) |
|
Atlantic Coastal Acquisition Corp Ii
ACAB's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Atlantic Coastal Acquisition Ii's sales fell
in II. Quarter 2024 from the same quarter a year ago.
Biotechnology & Pharmaceuticals industry recorded
deterioration of revenues by -0.89 %
Atlantic Coastal Acquisition Ii faced net loss in contrast to the net income a year ago in II. Quarter 2024
• More on ACAB's Growth
|
|
Atlantic Coastal Acquisition Ii realized a net loss in trailing twelve months.
Atlantic Coastal Acquisition Ii realized cash reduction of $ -2.98 per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.86.
• More on ACAB's Valuation
|
|
|
|
|
Atlantic Coastal Acquisition Ii realized net loss in trailing twelve months.
Atlantic Coastal Acquisition Ii realized cash outflow of $ -2.98per share in trailing twelve-month period. Biotechnology & Pharmaceuticals industry recorded net loss in trailing twelve months. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 6.86.
• More on ACAB's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2024 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com